For research use only. Not for therapeutic Use.
Sipatrigine is a multiple channels blocker potentially for the treatment of stroke. It has been shown to blocks multiple cardiac ion channels, cause triangulation of the ventricular action potential,and could have therapeutic potential for major depression and bipolar depression through antagonism of the two-pore-domain K+ channel TREK-1.
| Catalog Number | R036109 |
| CAS Number | 130800-90-7 |
| Synonyms | 2-(4-Methyl-1-piperazinyl)-5-(2,3,5-trichlorophenyl)-4-pyrimidinamine; 619C89; BW 619C89 |
| Molecular Formula | C15H16Cl3N5 |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | Soluble in DMSO > 10 mM |
| Storage | Store at RT |
| IUPAC Name | 2-(4-methylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)pyrimidin-4-amine |
| InChI | InChI=1S/C15H16Cl3N5/c1-22-2-4-23(5-3-22)15-20-8-11(14(19)21-15)10-6-9(16)7-12(17)13(10)18/h6-8H,2-5H2,1H3,(H2,19,20,21) |
| InChIKey | PDOCBJADCWMDGL-UHFFFAOYSA-N |
| SMILES | CN1CCN(CC1)C2=NC=C(C(=N2)N)C3=CC(=CC(=C3Cl)Cl)Cl |
| Reference | </br>1:Sipatrigine could have therapeutic potential for major depression and bipolar depression through antagonism of the two-pore-domain K+ channel TREK-1. Tsai SJ.Med Hypotheses. 2008;70(3):548-50. Epub 2007 Aug 20. PMID: 17703894 </br>2:The neuroprotective agent sipatrigine blocks multiple cardiac ion channels and causes triangulation of the ventricular action potential. Gao Z, Milnes JT, Choisy SC, Leach MJ, Hancox JC, James AF.Clin Exp Pharmacol Physiol. 2005 Dec;32(12):1088-96. PMID: 16445575 </br>3:Sodium channel blocking activity of AM-36 and sipatrigine (BW619C89): in vitro and in vivo evidence. Callaway JK, Castillo-Melendez M, Giardina SF, Krstew EK, Beart PM, Jarrott B.Neuropharmacology. 2004 Jul;47(1):146-55. PMID: 15165842 </br>4:Actions of sipatrigine, 202W92 and lamotrigine on R-type and T-type Ca2+ channel currents. Hainsworth AH, McNaughton NC, Pereverzev A, Schneider T, Randall AD.Eur J Pharmacol. 2003 Apr 25;467(1-3):77-80. PMID: 12706458 </br>5:Sipatrigine and oligodendrocyte and axonal pathology following transient focal cerebral ischaemia in the rat. McCracken E, Dewar D, McCulloch J.Neuroreport. 2003 Mar 3;14(3):517-20. PMID: 12634515 </br>6:Effects of extracellular pH on the interaction of sipatrigine and lamotrigine with high-voltage-activated (HVA) calcium channels in dissociated neurones of rat cortex. Hainsworth AH, Spadoni F, Lavaroni F, Bernardi G, Stefani A.Neuropharmacology. 2001 May;40(6):784-91. PMID: 11369032 </br>7:The neuroprotective agent sipatrigine (BW619C89) potently inhibits the human tandem pore-domain K(+) channels TREK-1 and TRAAK. Meadows HJ, Chapman CG, Duckworth DM, Kelsell RE, Murdock PR, Nasir S, Rennie G, Randall AD.Brain Res. 2001 Feb 16;892(1):94-101. PMID: 11172753 </br>8:Phase II clinical trial of sipatrigine (619C89) by continuous infusion in acute stroke. Muir KW, Holzapfel L, Lees KR.Cerebrovasc Dis. 2000 Nov-Dec;10(6):431-6. PMID: 11070372 </br>9:Inhibition of recombinant low-voltage-activated Ca(2+) channels by the neuroprotective agent BW619C89 (Sipatrigine). McNaughton NC, Hainsworth AH, Green PJ, Randall AD.Neuropharmacology. 2000 Apr 27;39(7):1247-53. PMID: 10760366 </br>10:Electrophysiology of sipatrigine: a lamotrigine derivative exhibiting neuroprotective effects. Calabresi P, Stefani A, Marfia GA, Hainsworth AH, Centonze D, Saulle E, Spadoni F, Leach MJ, Giacomini P, Bernardi G.Exp Neurol. 2000 Mar;162(1):171-9. PMID: 10716897 |
